Article

MCP-1 upregulates amylin expression in murine pancreatic β cells through ERK/JNK-AP1 and NF-κB related signaling pathways independent of CCR2. PLoS One 6:e19559

University of Padova, Medical School, Italy
PLoS ONE (Impact Factor: 3.23). 05/2011; 6(5):e19559. DOI: 10.1371/journal.pone.0019559
Source: PubMed

ABSTRACT Amylin is the most abundant component of islet amyloid implicated in the development of type 2 diabetes. Plasma amylin levels are elevated in individuals with obesity and insulin resistance. Monocyte chemoattractant protein-1 (MCP-1, CCL2) is involved in insulin resistance of obesity and type 2 diabetes. We investigated the effect of MCP-1 on amylin expression and the underlying mechanisms with murine pancreatic β-cell line MIN6 and pancreatic islets.
We found that MCP-1 induced amylin expression at transcriptional level and increased proamylin and intermediate forms of amylin at protein level in MIN6 cells and islets. However, MCP-1 had no effect on the expressions of proinsulin 1 and 2, as well as prohormone convertase (PC) 1/3 and PC2, suggesting that MCP-1 specifically induces amylin expression in β-cells. Mechanistic studies showed that although there is no detectable CCR2 mRNA in MIN6 cells and islets, pretreatment of MIN6 cells with pertussis toxin inhibited MCP-1 induced amylin expression, suggesting that alternative Gi-coupled receptor(s) mediates the inductive effect of MCP-1. MCP-1 rapidly induced ERK1/2 and JNK phosphorylation. Inhibitors for MEK1/2 (PD98059), JNK (SP600125) or AP1 (curcumin) significantly inhibited MCP-1-induced amylin mRNA expression. MCP-1 failed to induce amylin expression in pancreatic islets isolated from Fos knockout mice. EMSA showed that JNK and ERK1/2 were involved in MCP-1-induced AP1 activation. These results suggest that MCP-1 induces murine amylin expression through AP1 activation mediated by ERK1/2 or JNK. Further studies showed that treatment of MIN6 cells with NF-κB inhibitor or overexpression of IκBα dominant-negative construct in MIN6 cells significantly inhibited MCP-1-induced amylin expression, suggesting that NF-κB related signaling also participates in MCP-1-induced murine amylin expression.
MCP-1 induces amylin expression through ERK1/2/JNK-AP1 and NF-κB related signaling pathways independent of CCR2. Amylin upregulation by MCP-1 may contribute to elevation of plasma amylin in obesity and insulin resistance.

Download full-text

Full-text

Available from: Juan Chen, May 12, 2015
0 Followers
 · 
120 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The core pathology of sickle cell disease (SCD) starts with the erythrocyte (RBC). Aberration in MAPK/ERK1/2 signaling, which can regulate cell adhesion, occurs in diverse pathologies. Because RBCs contain abundant ERK1/2, we predicted that ERK1/2 is functional in sickle (SS) RBCs and promotes adherence, a hallmark of SCD. ERK1/2 remained active in SS but not normal RBCs. β(2)-adrenergic receptor stimulation by epinephrine can enhance ERK1/2 activity only in SS RBCs via PKA- and tyrosine kinase p72(syk)-dependent pathways. ERK signaling is implicated in RBC ICAM-4 phosphorylation, promoting SS RBC adhesion to the endothelium. SS RBC adhesion and phosphorylation of both ERK and ICAM-4 all decreased with continued cell exposure to epinephrine, implying that activation of ICAM-4-mediated SS RBC adhesion is temporally associated with ERK1/2 activation. Furthermore, recombinant ERK2 phosphorylated α- and β-adducins and dematin at the ERK consensus motif. Cytoskeletal protein 4.1 also showed dynamic phosphorylation but not at the ERK consensus motif. These results demonstrate that ERK activation induces phosphorylation of cytoskeletal proteins and the adhesion molecule ICAM-4, promoting SS RBC adhesion to the endothelium. Thus, blocking RBC ERK1/2 activation, such as that promoted by catecholamine stress hormones, could ameliorate SCD pathophysiology.
    Blood 12/2011; 119(5):1217-27. DOI:10.1182/blood-2011-03-344440 · 10.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Curcumin, the principal polyphenolic curcuminoid derived from the rhizome Curcuma longa, is present in an Indian spice, turmeric. Curcumin possesses antitumor, antioxidant, and anti-inflammatory properties, and has been studied as a cancer chemopreventive agent. Curcumin is extensively studied, evaluated and accepted for its wide range of medicinal properties. The therapeutic activities of curcumin for a wide variety of diseases such as diabetes, allergies, arthritis and other chronic and inflammatory diseases have been known for a long time. The mechanisms of therapeutic action of curcumin include inhibition of several cell signaling pathways at multiple levels, immune-modulation, effects on cellular enzymes such as cyclooxygenase and glutathione S-transferases and effects on angiogenesis and metastasis. It has ability to affect gene transcription and induce cell cycle arrest and apoptosis. Although curcumin is a highly pleiotropic molecule with an excellent safety profile targeting multiple diseases, it could not achieve its optimum therapeutic outcome in clinical trials, largely due to its low solubility and poor bioavailability. Based on the results of the clinical trials, curcumin can be developed as a therapeutic drug through improvement in formulations or delivery systems, enabling its enhanced absorption and cellular uptake. In this review article, we provide a comprehensive outlook for the therapeutic potential of curcumin, and discuss future strategies and potential challenges involved in the use of curcumin.
    Nutrition, Diet and Cancer, 01/2012: pages 413-457; , ISBN: 978-94-007-2922-3
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To clarify the role and mechanism of CCL2 in regulating the biological functions of endometrial stromal cells (ESCs). The CCL2 effect on the viability, proliferation, and invasion in the eutopic ESCs from endometriosis. Research laboratories. Patients with endometriosis aged 23-47 years. None. Signal transduction and downstream molecules from CCR2. We have found that the secretion of CCL2 by the eutopic ESCs from endometriosis is higher than that of healthy ESCs without endometriosis. The CCL2 can enhance the viability, proliferation, and invasion of ESCs in a dosage and time-dependent manner. Anti-CCL2 neutralizing antibody and CCR2 antagonist can completely abolish the increase in viability, proliferation, and invasiveness of ESCs induced by CCL2. The CCL2 can increase the expression of proliferating cell nuclear antigen, survivin, and matrix metalloproteinase 2, and decrease the expression of tissue inhibitor of metalloproteinase 1 and 2, and promote the viability, proliferation and invasiveness of ESCs by activating Akt and MAPK/Erk1/2 signal pathway, but not p38 and JNK signal pathway. CCL2 might play an important role in regulating the functions of ESCs through Akt and MAPK/Erk1/2 signal pathway, and overexpression of CCL2 in ESCs and peritoneal fluid (PF) would lead to onset and development of endometriosis.
    Fertility and sterility 01/2012; 97(4):919-29. DOI:10.1016/j.fertnstert.2011.12.049 · 4.59 Impact Factor
Show more